Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
November 20, 2025

Wall Street Sputters on AI Jitters: Nasdaq Slide, Walmart Exceeds, & Exact Sciences’ $23B Buyout Lead Market Moves – Nov. 20,2025 -( $EPRX $EXAS $MENS $MTWO $PACS $VIX $WMT Rise!)

In the end, Thursday looked like a market attempting to renegotiate its relationship with AI, tariffs and the Fed all at once—discovering, not for the first time, that even in an age of algorithms and GLP‑1s, gravity still has a vote.

Indexes and Fear soars

The S&P 500 spent the morning flirting with a deeper selloff prior to closing down 1.56% at 6,538.76. The Dow Jones Industrial Average  fared a little better, closing down close to .84% at 45,752.26. The Nasdaq Composite  staged the day’s main act: an early surge that morphed into a sharp reversal, ultimately finishing lower by more than 2.15% at 22,078.05 as AI darlings swung from heroes to suspects in a single session. The Russell 2000 also took a hit dropping 1.82% at 2,305.11 at the close.  The markets fear gauge The VIX jumped once again closing at 426.42, +11.67% and is now up a whopping 33.23% over the last 5-days.

Macroeconomic data and shutdown aftershocks

The macro calendar was headlined by a long‑delayed September jobs report, finally released after the recent government shutdown, showing payroll growth of 119,000, a touch better than expected, even as the unemployment rate climbed to 4.4%, its highest level since 2021. Wage growth remained moderate at 0.2% for the month and 3.8% year over year, a combination that keeps the “softish landing” story alive but gives nobody at the Fed permission to relax. Weekly jobless claims slipped to 220,000, reinforcing the picture of a labor market that is cooling, but not cracking, even as agencies scramble to catch up on a backlog of economic releases now being rescheduled post‑shutdown.

Fed, yields and the curve

Treasuries spent the day grinding as investors weighed firmer labor data against lingering growth worries, with the 10‑year yield sliding toward roughly 4.09% & the 2-yr closing lower at 3.545%. The curve remained inverted across key maturities, an ongoing reminder that the bond market still believes in a future slowdown even as equity traders continue to rent optimism on a daily basis. Fed officials, still navigating policy with patchy data after the shutdown, signaled caution about further rate cuts, leaving markets betting on a slower and more begrudging easing path heading into the December FOMC decision.

Tariffs, trade and Washington backdrop

Trade policy remained a live wire: the administration prepared an order to lower tariffs on a range of consumer staples such as beef, tomatoes, coffee and bananas, even as broader Trump‑era tariff frameworks—on China and select Latin American partners—continue to reshape global supply chains. At the same time, the White House moved to provide targeted tariff relief on agricultural staples, sending a small wave of relief through food and retail supply chains that have been whiplashed by rolling trade actions. On Capitol Hill, the government shutdown is now officially in the rearview mirror after ending on November 12, but the political compromise that reopened agencies simply kicked the next subsidies fight into December, ensuring fiscal drama remains a recurring feature rather than a one‑off shock.

Walmart

Walmart’s (WMT, $107.11, +6.46%) latest earnings report is a masterclass in retail resilience, with the Bentonville behemoth posting a 5.8% year-over-year revenue jump to $179.5 billion for Q3 2025—exceeding Wall Street’s expectations by a healthy margin. The numbers tell a story of disciplined execution: same-store sales rose 4.5%, e-commerce surged by 28%, and the retailer’s global advertising arm saw a 53% spike in revenue, fueled by its Walmart Connect retail media business. As the holiday shopping season looms, Walmart is not just surviving inflation and cautious consumers—it’s thriving, thanks to a relentless focus on affordability, operational efficiency, and a tech-forward strategy that’s redefining the retail landscape.

Big pharma and chips: Eli Lilly and TSMC

Eli Lilly (LLY, $1,043.29, -.60%) spent another session basking in the rarefied air near a $1 trillion valuation, with investors still willing to pay up for GLP‑1‑powered growth even as valuation metrics hover well above sector norms. The company’s obesity and diabetes franchise continues to convince the market that Lilly is less a pharma name and more an annuity on global waistlines, keeping the stock’s year‑to‑date gains (+35.14%) materially ahead of peers. Analyst estimates for 2025 and 2026 have marched steadily higher over the past month, reinforcing the sense that multiple expansion is at least partially backed by rising earnings power.

Taiwan Semiconductor Manufacturing Company (TSM, $277.50, -1,.72%) have analysts maintaining a broadly bullish stance after the company recently beat earnings expectations, delivered 40% year‑over‑year revenue growth, and boosted its dividend. Shares have been trading near record territory, reflecting investors’ view that TSMC has become a tollbooth operator on the global AI build‑out, collecting margin every time another hyperscaler decides it needs more cutting‑edge capacity. With return on equity north of 36% and a consensus “Moderate Buy” rating, the stock remains firmly embedded in the market’s shortlist of AI hardware champions.

Mega‑cap tech: Alphabet, NVIDIA, Apple, Tesla, Broadcom, Meta

Alphabet (GOOG, $289.98)  spent the second half of the day on the defensive, with the communication‑services sector under pressure and the stock trading lower as investors took profits in names that had led much of this year’s rally. Despite the pullback, the company remains central to AI and cloud narratives, keeping it squarely in the camp of “essential but occasionally over‑owned” in portfolio manager conversations and is up 52.27% YTD.

NVIDIA (NVDA, $80.64, -3.15%) delivered the latest installment of its high‑stakes AI saga, with shares sliding roughly 3% even after strong earnings as investors fretted that capex‑heavy AI spending might be starting to resemble a gold rush where shovels have become uncomfortably expensive. The stock’s reversal weighed heavily on the broader Nasdaq and reignited chatter about whether AI valuations have sprinted too far ahead of cash flows, at least for this stage of the cycle.

Apple (AAPL, $266.25, -.86%) traded in sympathy with the broader mega‑cap complex, caught between a resilient installed base and recurring questions about iPhone growth, China exposure, and the durability of its services‑driven multiple. The name remains a cornerstone in many large portfolios, which means days of macro‑driven de‑risking often translate into mechanical selling pressure rather than any dramatic change in the long‑term thesis and is up 632% YTD.

Tesla (TSLA, $395.23, -2.17%) continued its habit of turning every macro wobble into a volatility showcase, with the stock caught between concerns over EV demand, intensifying competition and the promise of software‑driven margins and AI‑enabled autonomy. As usual, the market treated the name less like an automaker and more like an option on several possible futures, some profitable, others merely cinematic.

Broadcom (AVGO, $346.82, -2.14%) stayed near the center of the AI and networking trade, having recently logged outsized gains alongside other big‑cap chip names that feed data‑center demand. Investors continue to reward the company’s mix of semiconductor and software franchises, viewing it as a diversified way to stay exposed to AI and cloud spending without going all‑in on a single product cycle and is up +49.59% YTD.

Meta Platforms (META, $589.15, -.20%) saw choppy trading as the market weighed still‑robust engagement and advertising growth against elevated capex plans for AI infrastructure and the company’s ongoing metaverse ambitions. The stock remains emblematic of the current AI moment: high cash generation underwriting high experimentation, with the market alternately celebrating and second‑guessing that equation and is up .62% YTD.

Nokia, McDonald’s, Rio Tinto, Oracle and Intel

Nokia (NOK, $5.87, -2.65%) remained more of a macro and telecom‑cycle proxy than a momentum favorite, with the market still focused on when carrier capex and 5G spending will re‑accelerate enough to lift the company’s top line. Sentiment around the network equipment space remains cautious amid uneven global deployment trends and pricing pressure and the stock is up +32.51% YTD.

McDonald’s (MCD, $304.16, +.47%) traded as a defensive stalwart, with its global footprint and pricing power keeping the stock in favor among investors seeking earnings resilience in a world of volatile rates and tariffs. Even as input costs and wage pressures ebb and flow, the chain’s ability to adjust menus and price points continues to underpin steady cash generation and is up 4.92% YTD with ~2.46% forward dividend.

Rio Tinto Group (RIO, $68.78, -.94%)  spent the day shadowing the broader materials complex, where concerns about global growth and China’s industrial demand left miners struggling to gain traction. With the yield curve signaling slower growth ahead, the market remains wary of cyclical exposures tied to steel, construction and heavy industry​, but shares are up +16.95% YTD with a heathery +5.37% forward dividend.

Oracle (ORCL, $210.69, -6.58%) after recently enjoying support from its expanding cloud and AI‑adjacent database franchises.. As enterprises slowly modernize legacy workloads, Oracle’s cloud transition continues to earn it a place in many AI and infrastructure baskets, whiles shares are up +26.43% YTD.

Intel (INTC, $33.62, -4.24%) traded in the long shadow of higher‑growth chip peers, as investors balanced optimism about its foundry ambitions and government‑backed domestic capacity against the reality of execution risk and still‑modest profitability in newer initiatives. In the current market, Intel is currently being treated less like a pure AI winner and more like a turnaround‑plus‑industrial‑policy story, however shares are up 67.68% YTD.

M&A and IPOs: Abbott–Exact Sciences and new listings

Deal‑makers finally stole a bit of the AI spotlight as Abbott  confirmed plans to acquire Exact Sciences (EXAS, $100.67, +16.81%) in a cash transaction valuing the cancer‑diagnostics specialist at roughly $21–23 billion, or about $105 per share. Exact Sciences shares surged more than 17% while Abbott (ABT) slipped 1.73% to $123.97, a textbook reaction when the prey is pricey but strategically prized. The deal folds Cologuard and Oncotype DX into Abbott’s broader diagnostics empire, diversifying away from fading COVID testing revenue and signaling that large‑cap healthcare is willing to pay up for durable oncology growth.

On the new‑issue front, Central Bancompany (CBCY, $23.75)  made its market debut on Nasdaq, pricing 17.8 million Class A shares at 21 dollars each, with trading beginning today and gross proceeds estimated around 373 million dollars before fees. While overall 2025 IPO volumes have already run more than 60% ahead of last year, today’s listing underscored that financials—especially in areas perceived as insulated from tariff turbulence—remain in demand.

Commodities: gold, silver and oil

Gold drifted lower by .12% to $4,077.00/oz.. Even with today’s slippage, bullion remains elevated on a multi‑month view, supported by lingering geopolitical risk and the prospect of slower—but not reversed—Fed easing. Silver fared worse in percentage terms, sliding roughly 1.02% to $50.335 as traders leaned into the metal’s dual identity as both precious and industrial, a combination that has struggled to shine in the face of global growth worries. Crude oil prices dropped again by .83% to $58.76/bbl.

Crypto: bitcoin

Bitcoin (BTC) slipped back below the psychologically charged 90,000‑dollar level, dropping -3.19% to $87,448.65.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4470), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.21, +.16%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4011), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.07) and M2i Global, Inc. (MTWO, $.0999, +.10%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.76) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $32.85) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

Exact Sciences Corp. (NASDAQ: EXAS, $86.18, +23.68%), a leading provider of cancer screening and diagnostic tests, announced (Nov. 7) pivotal clinical validation results from the ALTUS study (NCT: 05064553). The prospective, head-to-head trial demonstrated that the company’s Oncoguard® Liver blood test delivers superior early-stage and overall sensitivity for hepatocellular carcinoma (HCC) — the most common form of liver cancer — compared to the current standard of care.

Nokia (NOK, 5.87) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. The market, in classic fashion, responded to this vision of future riches by sending the stock currently lower on the day, but is currently up +45.54% over the last year at $6.04

Jyong Biotech Ltd. (Nasdaq: MENS, $32,80, +12.44%), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP).

PACS Group, Inc. (NYSE: PACS, 26.14, +55.32%), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced (Nov. 19) operating results for the third quarter of 2025. The Company has completed the previously announced Restatement of its financial statements for the three months ended March 31, 2024, and for the three and six months ended on June 30, 2024 (the “Restatement”), and is current with its SEC filing obligations.

The Sources

  1. https://www.bloomberg.com/news/articles/2025-11-19/stock-market-today-dow-s-p-live-updates
  2. https://www.seattlepi.com/business/article/how-major-us-stock-indexes-fared-thursday-21199395.php
  3. https://www.briefing.com/stock-market-update/archive
  4. https://www.wsj.com/livecoverage/jobs-report-bls-september-stock-market-today-11-20-2025
  5. https://www.bea.gov/news/blog/2025-11-20/economic-release-schedule-updates-gdp-and-personal-income-and-outlays
  6. https://www.cnbc.com/2025/11/20/jobs-report-september-2025.html
  7. https://www.reuters.com/business/us-job-growth-beats-expectations-september-unemployment-rate-rises-44-2025-11-20/
  8. https://tradingeconomics.com/united-states/20-year-bond-yield
  9. https://www.tradecomplianceresourcehub.com/2025/11/17/trump-2-0-tariff-tracker/
  10. https://www.bhfs.com/insight/white-house-provides-tariff-relief-for-consumer-agricultural-staples/
  11. https://en.wikipedia.org/wiki/2025_United_States_federal_government_shutdown
  12. https://www.nasdaq.com/articles/beyond-glp-1-eli-lillys-expanding-drug-portfolio-lifts-sales
  13. https://www.biospace.com/business/eli-lilly-enters-uncharted-territory-as-market-cap-nears-1t
  14. https://www.marketbeat.com/instant-alerts/filing-taiwan-semiconductor-manufacturing-company-ltd-tsm-shares-sold-by-cumberland-partners-ltd-2025-11-20/
  15. https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-rise-as-stocks-pause-sell-off-streak-before-nvidia-earnings-210332709.html
  16. https://www.nasdaq.com/articles/my-5-top-ranked-stocks-buy-now-november
  17. https://www.financialjourney.com/campaigns/monthly-market-insights
  18. https://www.ii.co.uk/analysis-commentary/ii-tech-focus-palantir-amazon-tesla-strategy-cisco-systems-ii537171
  19. https://www.morningstar.com/news/marketwatch/20251120261/these-15-stocks-are-still-showing-momentum-and-a-market-beating-edge
  20. https://www.marketbeat.com/instant-alerts/promising-technology-stocks-to-research-november-14th-2025-11-14/
  21. https://www.jpmorgan.com/insights/investing/investment-strategy/business-exit-strategies-for-startup-founders-and-entrepreneurs
  22. https://stockanalysis.com/ipos/2025/
  23. https://www.cnbc.com/2025/11/17/stock-market-today-live-updates.html
  24. https://www.reuters.com/business/insurance-ipos-hit-20-year-high-wall-street-after-tariff-driven-chaos-2025-11-20/
  25. https://abbott.mediaroom.com/2025-11-20-Abbott-to-acquire-Exact-Sciences,-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments
  26. https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-bolsters-diagnostics-portfolio-with-up-23-billion-buyout-exact-sciences-2025-11-20/
  27. https://finance.yahoo.com/news/exact-sciences-stock-jumps-abbott-130958219.html
  28. https://www.prnewswire.com/news-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments-302621643.html
  29. https://www.investors.com/news/technology/exact-sciences-stock-abbott-laboratories-rumored-takeover/
  30. https://www.stocktitan.net/news/CBC/central-bancompany-inc-announces-pricing-of-initial-public-0hvbyec63jmw.html
  31. https://forex24.pro/silver-price-forecast/silver-forecast-xag-usd-for-november-20-2025/
  32. https://www.kitco.com/price/precious-metals
  33. https://www.economies.com/crypto/analysis/forecast-update-for-bitcoin–20-11-2025-122831
  34. https://finance.yahoo.com/quote/%5EGSPC/history/
  35. https://www.cnbc.com/2025/11/20/abbott-to-acquire-exact-sciences.html
  36. https://www.massdevice.com/abbott-confirms-21b-exact-sciences-acquisition/
  37. https://www.barrons.com/articles/exact-sciences-stock-abbott-acquisition-92c76a15
  38. https://www.nasdaq.com/articles/stock-market-news-nov-20-2025
  39. https://stockanalysis.com/stocks/tsm/history/
November 20, 2025

Elon Musk, Jensen Huang and Saudi Arabia’s Big Bet on AI Factories and Space Computing -( $NVDA $TSLA $SPY )

In a week where global CEOs descended on Washington, sharing canapés and quips at the U.S.-Saudi Arabia investment forum, two industry titans—Elon Musk (SpaceX, Tesla, xAI) and Jensen Huang (Nvidia)—took the stage to debate the trajectory of technology, wealth, and, for the love of C3PO, why humanity may soon need a robot butler for every household.

The New Special Relationship: Silicon, Not Sand

This year’s event, held under the watchful eyes of U.S. President Trump and Saudi Crown Prince Mohammed bin Salman (MBS), might have looked like a routine handshake summit, but the undertow was all business. Sectors from energy and health care to aerospace and finance are finding common ground in digital ambition: Saudi Arabia seeks to leap from oil rigs to “AI factories,” while U.S. innovators are hungry for international allies and, one assumes, some extra sun-drenched data centers.youtube​

As diplomats reminisced about joint ventures from the industrial age, Musk and Huang heralded what they call the “intelligence age,” fueled by robotic labor, generative AI, and investments as big as a Saudi sovereign wealth fund on a payday. In a moment that managed to be both strategic and lightly comedic, a speaker counted “7 to 8 trillion dollars” in market cap represented on the stage, then promptly lost count—some numbers now require quantum processors.youtube​

Musk on Wealth, Work, and the Rise of the Robots

Never one to shy from audacious predictions, Musk declared that humanoid robots will dwarf the mobile phone market—think C3PO, but with better battery life. “There are no actually useful humanoid robots yet,” he quipped, promising that Tesla will deliver the first. Whether this revolutionizes productivity or just gives everyone an excuse to avoid chores remains to be seen. Musk’s vision: work itself will become optional, reduced to the artisanal status of backyard vegetable gardening. “If you want to work, you can, but you won’t have to,” he mused, inviting references to Iain M. Banks’ famed Culture novels, where money is as outdated as dial-up internet.

Will AI and robots truly eliminate poverty? Musk is bullish, not just on technology, but on the promise of these advances to make “everyone wealthy”—provided, of course, one has robust access to electricity and mass. The only real constraints, in his opinion, will be the laws of physics. Currency, he jokes, may soon be as irrelevant as memorizing phone numbers in the age of contacts apps.

Huang’s Take: More Radiologists Than Ever—and More Work for Everyone

Jensen Huang, meanwhile, offered a counterintuitive observation: despite predictions that AI would make radiologists obsolete, the field is hiring more than ever. AI tools haven’t replaced specialists so much as turbocharged their workload, letting them examine vast numbers of images, modalities, and, ideally, spend more time with patients. In the near-term, he predicts, AI will make everyone more productive—and paradoxically, even busier. With a laugh, he noted that the only impending shortage in the intelligence age may be the supply of good ideas, not jobs.

Huang also dropped some hard statistics: in just six years, the share of CPUs in the world’s top supercomputers plunged from 90% to less than 15%, while Nvidia’s “accelerated computing” (think: GPUs) rose to dominance. The internet (and the modern financial sector) now runs on recommendation engines and generative AI, systems hungry for computational muscle. “What is happening underneath is a movement from general purpose computing to accelerated computing; all of it is justified,” he said, waving off AI bubble fears in the manner of a man who owns shovels just as the gold rush begins.youtube​

Announcements: AI in Desert Sands, and Supercomputers in Orbit

Saudi Arabia plans to fuel the next wave with some genuine moonshots: Musk announced a partnership with xAI and Nvidia to build a 500-megawatt AI data center (in phases, because even Musk can’t disrupt the laws of power distribution overnight). Jensen Huang nodded to further projects with AWS and Humane (an AI startup, not the virtue), and even hinted at supercomputers for quantum error correction. “Off the ground and off the charts,” he beamed, earning laughter for the double meaning.

And about AI in space? “If civilization continues, it’s inevitable,” Musk declared, noting that the cost of AI compute in space—where it’s always sunny—may soon outpace anything available on Earth. Supercomputers will shrink, cooling will simplify, and the only thing left to do will be dividing up the sun’s energy—give or take a billionth.

Bubble? What Bubble?

Asked directly if the AI surge is a bubble, Huang pointed not to hype, but to the underlying shift in compute itself. With physical limits on Moore’s Law and infinite data to process, the need for accelerated computing is real, immediate, and, for the foreseeable future, not speculative froth but an infrastructure revolution.youtube​

As the event wrapped with dignitaries, tech visionaries, and at least one shot at a punchline about “our bosses”—the President and the Crown Prince—one thing was clear: in the new era, national fortunes may depend on the ability to move from barrels to bytes, and to laugh, perhaps, as we race robots toward a future none of us can quite count out.

    November 20, 2025

    Nvidia CEO Jensen Huang Slams ‘AI Bubble’ Fears as Demand Soars for Chips -( $NVDA $META $MSFT $AMZN )

    Nvidia (NVDA) CEO Jensen Huang has delivered a masterclass in corporate optimism, dismissing AI bubble fears with the kind of swagger usually reserved for Silicon Valley’s most confident CEOs. In a recent earnings call that sent shares soaring yesterday after the close, Huang argued that the current AI boom is not a speculative frenzy, but a structural transformation—akin to the shift from mainframes to PCs, or the dawn of the internet. While skeptics warn of circular investing and unsustainable spending, Huang insists Nvidia is riding a wave of real, lasting change, not just hype.

    The Case Against the AI Bubble

    Huang’s rebuttal to bubble talk is both technical and philosophical. He outlined three key transitions fueling demand for Nvidia’s chips: the shift from CPUs to GPUs, the rise of AI-driven applications, and the emergence of “agentic” and “physical” AI systems. The slowdown of Moore’s Law, he noted, has pushed traditional computing to its limits, forcing industries from data processing to ad recommendations to embrace GPU-powered systems. “From our vantage point, we see something very different,” Huang said, brushing off concerns that the AI surge is a bubble. Instead, he sees a tipping point where AI is not just improving existing tools but creating entirely new categories of software and hardware, from coding assistants to robotics. Nvidia’s unified architecture, he argued, is uniquely positioned to power this next wave of infrastructure growth.

    Circular Investing: A Self-Fulfilling Prophecy?

    The skepticism around the AI boom centers on the circular nature of some of Nvidia’s deals. Cloud providers and tech giants are investing in AI startups, which in turn use those funds to buy Nvidia chips, creating a feedback loop that some fear could end badly. For example, a $100 billion investment in OpenAI was announced in September, with the understanding that OpenAI would purchase Nvidia chips. Similarly, Anthropic recently committed to acquiring $30 billion in computing capacity from Microsoft Azure, powered by Nvidia chips, in exchange for investments from both tech giants. These reciprocal funding agreements have raised eyebrows, with some analysts warning that the cycle could collapse if the companies involved fail to turn a profit. Huang, however, remains unfazed. “Sales of Blackwell are extraordinary, and our cloud GPUs are completely sold out,” he said, reinforcing his view that the current surge in AI spending is not expected to wane soon.

    The Humor in the Hype

    Huang’s tone during the earnings call was laced with a touch of sophisticated humor. When asked about the circular investing concerns, he quipped, “If you’re worried about the bubble, just look at our order book. It’s not a bubble if the demand is real.” He also joked about the “circularity” of the deals, saying, “We’re not just selling chips; we’re selling the future. And if the future is circular, so be it.” This blend of technical insight and wry humor has become a hallmark of Nvidia’s leadership, helping to reassure investors even as the company’s reliance on a handful of major customers grows. In the third quarter, 61% of Nvidia’s $57 billion in revenue came from just four unnamed customers, up from 56% in the previous quarter. Past announcements suggest these could include Microsoft (MSFT), Meta (META), and Oracle (ORCL).

    The Road Ahead: Infrastructure and Beyond

    Huang acknowledged that building the required data centers to meet the vision of AI-powered everything will require an enormous amount of land and power. “We’ve now established partnerships with so many players in land and power and (data center buildings), and of course, financing these things,” he said. “None of these things are easy, but they’re all tractable, and they’re all solvable things.” As companies like Google (GOOG) and Amazon (AMZN) design their own AI chips, some analysts question whether Nvidia’s dominance is sustainable. But for now, Huang’s message is clear: the AI boom is not a bubble, but a transformation that will reshape industries for years to come.

    The Sum…

    Nvidia’s story is a reminder that in the world of tech, the line between visionary and bubble is often drawn in hindsight. For now, Huang is betting that the future is not just bright, but profitable—and he’s inviting investors to join him on the ride.

    The Sources

    1. https://timesofindia.indiatimes.com/technology/tech-news/nvidia-ceo-jensen-huang-talks-about-the-biggest-fear-everyone-has-about-ai-companies-from-our-point-/articleshow/125456686.cms
    2. https://economictimes.com/news/new-updates/nvidia-ceo-jensen-huang-breaks-silence-on-biggest-fear-surrounding-ai-bubble/articleshow/125458939.cms
    3. https://www.investing.com/news/stock-market-news/tipping-point-or-bubble-nvidia-ceo-sees-ai-transformation-while-skeptics-count-the-risks-4369237
    4. https://www.cnn.com/2025/11/19/tech/nvidia-earnings-ai-bubble-fears
    5. https://www.janushenderson.com/en-gb/investor/article/quick-view-how-did-nvidias-earnings-call-address-ai-bubble-concerns/
    6. https://www.morningbrew.com/stories/2025/11/20/nvidia-blows-bubble-fears-and-expectations-away
    7. https://www.reuters.com/world/china/ai-leader-nvidia-forecasts-fourth-quarter-revenue-above-estimates-2025-11-19/
    8. https://www.nytimes.com/2025/11/20/business/dealbook/nvidia-ai-boom.html
    9. https://www.youtube.com/watch?v=cAJBA31iu3g
    10. https://www.bloomberg.com/news/articles/2025-11-20/nvidia-earnings-squash-ai-bubble-fears-big-take-podcast
    November 20, 2025

    Abbott’s Cancer Diagnostics $21B Gamble: The Exact Sciences Buyout Explained -( $ABT $EXAS $IBB $IYH )

    Abbott Laboratories (ABT) is making headlines with its latest $21 billion cash deal to acquire Exact Sciences (EXAS), a move that not only sends ripples through the diagnostics world but also gives Wall Street’s quants and humorists some fresh material for dinner party banter. Forget colonoscopies: the big story now is whether Abbott, having mastered everything from diabetes to infectious disease testing, can pull off its much-anticipated entrance into the $60 billion U.S. cancer screening arena—without tripping over the price tag or institutional egos.

    The Corporate Chess Match

    In this sector-defining transaction, Abbott is offering Exact Sciences shareholders $105 per share, representing a 22–51% premium and enough zeros to make any biotech C-suite wish they’d developed a colorectal test as catchy as Cologuard. While Exact’s Madison, Wisconsin headquarters will remain intact (no cheese plate disruption here), CEO Kevin Conroy will transition to an advisory role—presumably to ensure that Abbott learns how to spell “Oncotype DX” correctly at board meetings.

    Diagnosing Growth: Financials and Foresight

    Abbott is absorbing Exact’s estimated $1.8 billion in net debt, while betting the farm on the planned 2026 closing date and regulatory blessings just shy of sainthood. Exact is expected to deliver $3 billion in revenue this year, with growth rates in the high teens; this will push Abbott’s total diagnostics revenue to an impressive $12 billion annually once the ink dries—an expansion that should help paper over those post-pandemic COVID test sales doldrums.

    Strategic Humor and Market Satire

    As industry analysts point out, Abbott didn’t just buy a box of lab results—they acquired the entire narrative franchise. TD Cowen dubs this deal a “revitalization,” while Leerink calls it “sector-defining.” Wall Street wits, meanwhile, are abuzz: Was the real due diligence performed via a Cologuard kit after a particularly acrimonious earnings call? Does Abbott’s pivot from sniffing out viruses to screening for more elusive cellular mischief signal a new era for consumer diagnostics, or just retail therapy on a grand scale?

    Sector Implications: A New Growth Engine

    Abbott’s deal is poised to transform the company’s growth pathway, bringing advanced noninvasive screening tests and precision oncology diagnostics to the fore. Not only does this acquisition shore up Abbott’s diagnostics vertical, but it also validates the rapidly evolving central lab business model—and perhaps gives new meaning to the phrase “healthcare consolidation,” minus any digestive discomfort.

    The Sum…

    Abbott’s multi-billion-dollar bet on Exact Sciences shows that humor and innovation both pay dividends—so long as you’ve got the market-leading test, a hefty bank balance, and a CEO who knows how to let go gracefully. Investors, take note: It’s not every day that colorectal cancer screening becomes the punchline and the windfall—at least not in Madison.

    The Sources

    1. https://www.wsj.com/business/deals/abbott-to-acquire-exact-sciences-for-21-billion-8147b973
    2. https://www.biopharmadive.com/news/abbott-acquire-exact-sciences/806058/
    3. https://www.forbes.com/sites/brucejapsen/2025/11/20/abbotts-21-billion-exact-sciences-deal-fills-void-of-lost-covid-test-sales/
    4. https://www.prnewswire.com/news-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments-302621643.html
    5. https://www.pharmexec.com/view/abbott-21-billion-definitive-agreement-acquiring-exact-sciences
    6. https://www.bloomberg.com/news/articles/2025-11-20/abbott-to-buy-cologuard-maker-exact-sciences-for-21-billion
    7. https://www.barrons.com/articles/exact-sciences-stock-abbott-acquisition-92c76a15
    8. https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-bolsters-diagnostics-portfolio-with-up-23-billion-buyout-exact-sciences-2025-11-20/
    9. https://www.jsonline.com/story/news/2025/11/20/abbott-to-buy-madison-based-exact-sciences-in-up-to-23-billion-deal/87370349007/
    10. https://www.marketwatch.com/story/why-abbott-is-paying-21-billion-for-exact-sciences-and-its-cologuard-cancer-test-43dd31f9
    11. https://abbott.mediaroom.com/2025-11-20-Abbott-to-acquire-Exact-Sciences,-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments
    12. https://www.exactsciences.com/newsroom/press-releases
    13. https://www.mmm-online.com/news/abbott-buys-exact-sciences/
    14. https://www.exactsciences.com/newsroom/press-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision
    November 20, 2025

    Walmart’s $179B Quarter: E-Commerce Boom & New Nasdaq Ambitions -( $WMT $DIA $SPY )

    Walmart’s (WMT) latest earnings report is a masterclass in retail resilience, with the Bentonville behemoth posting a 5.8% year-over-year revenue jump to $179.5 billion for Q3 2025—exceeding Wall Street’s expectations by a healthy margin. The numbers tell a story of disciplined execution: same-store sales rose 4.5%, e-commerce surged by 28%, and the retailer’s global advertising arm saw a 53% spike in revenue, fueled by its Walmart Connect retail media business. As the holiday shopping season looms, Walmart is not just surviving inflation and cautious consumers—it’s thriving, thanks to a relentless focus on affordability, operational efficiency, and a tech-forward strategy that’s redefining the retail landscape.

    A Retail Giant’s Holiday Playbook

    Walmart’s latest quarter was driven by a surge in both transactions and average ticket size, with shoppers increasingly drawn to its value proposition amid a more price-sensitive environment. The retailer’s U.S. grocery segment remains a powerhouse, accounting for about half of its roughly 7,400 temporary price reductions—proof that Walmart is still the go-to for bargain hunters and budget-conscious families. Meanwhile, international sales climbed 10.8%, led by strong performances in India and China, further diversifying Walmart’s global footprint.

    E-Commerce: The New Engine of Growth

    If there’s a hero in Walmart’s earnings narrative, it’s e-commerce. Online sales jumped 28%, marking the seventh consecutive quarter of double-digit growth in the segment. The retailer’s store-based delivery network played a starring role, with one-third of recent deliveries arriving in under three hours and 20% in less than 30 minutes. This speed, combined with a growing marketplace and third-party seller ecosystem, has cemented Walmart’s position as a tech-savvy competitor to Amazon.

    Wall Street’s Holiday Cheer

    Analysts have responded with optimism, raising Walmart’s full-year net sales forecast to between 4.8% and 5.1%—a move that reflects confidence in the retailer’s ability to maintain momentum even as other big-box chains scale back expectations. Adjusted EPS reached $0.62, two cents above consensus, while net income surged 33% year-over-year to $6.14 billion. Walmart’s operating margin held steady at 3.7%, a testament to its ability to manage costs while driving growth.

    The Nasdaq Gambit

    In a move that signals Walmart’s ambition to be seen as a technology leader, the company announced plans to shift its stock listing from the New York Stock Exchange to Nasdaq in December. This symbolic gesture underscores Walmart’s transformation from a traditional retailer to a digital powerhouse, leveraging AI, retail media, and omnichannel fulfillment to capture market share across income groups.

    The Takeaway

    Walmart’s Q3 performance is a reminder that in retail, size and scale still matter—but so does innovation. As competitors grapple with economic headwinds, Walmart is not just weathering the storm; it’s setting the pace, offering shoppers value, speed, and choice, all while positioning itself for a tech-driven future. The message to Wall Street is clear: when it comes to retail, Walmart is still playing offense, and the holidays may be just the beginning.

    The Sources…

    1. https://finance.yahoo.com/news/walmart-nyse-wmt-exceeds-q3-121424520.html
    2. https://markets.financialcontent.com/wral/article/marketminute-2025-11-20-walmart-defies-economic-headwinds-with-stellar-q3-lifts-outlook-amidst-tech-driven-transformation
    3. https://www.reuters.com/business/walmart-boosts-outlook-again-plans-move-nasdaq-2025-11-20/
    4. https://www.grocerydive.com/news/walmart-us-grocery-ecommerce-growth-third-quarter-fiscal-2026/806037/
    5. https://www.nytimes.com/2025/11/20/business/walmart-holiday-sales.html
    6. https://www.barrons.com/articles/walmart-earnings-stock-price-6ed3528c
    7. https://www.foxbusiness.com/economy/walmart-strong-quarter-shows-americans-still-spending
    8. https://www.digitalcommerce360.com/article/walmart-online-sales/
    9. https://www.cnbc.com/2025/11/20/walmart-wmt-q3-2026-earnings.html
    10. https://www.bloomberg.com/news/articles/2025-11-20/walmart-lifts-outlook-as-e-commerce-gains-overcome-economic-woes
    11. https://www.investors.com/news/walmart-earnings-q3-dow-jones-wmt-stock-target-tgt-stock/
    12. https://www.businessinsider.com/walmart-strong-sales-retail-industry-struggles-2025-11
    13. https://corporate.walmart.com/news/2025/11/20/walmart-releases-q3-fy26-earnings
    14. https://www.nbcnews.com/business/business-news/walmart-earnings-ecommerce-rcna244853
    15. https://www.investing.com/news/company-news/walmart-q3-fy26-slides-revenue-jumps-6-ecommerce-surges-27-93CH-4370882
    16. https://www.wsj.com/business/retail/walmart-wmt-q3-earnings-report-stock-2025-f5c45d8b
    17. https://finance.yahoo.com/news/walmart-earnings-sales-top-expectations-as-company-raises-full-year-forecasts-120530231.html
    18. https://progressivegrocer.com/walmarts-q3-sales-growth-led-momentum-e-commerce
    19. https://www.axios.com/2025/11/20/walmart-earnings-doug-mcmillon-john-furner
    20. https://finance.yahoo.com/video/walmart-may-had-strong-q3-150640922.html
    November 20, 2025

    Three Mile Island Returns: Why Nuclear Energy Is Back in the S&P 500 Spotlight -( $CEG $OKLO $MSFT $SPY )

    Constellation Energy (CEG $357.48, +59.80% YTD), the $40 billion titan of electrons whose stock has been radiating in the S&P 500 like a newly uncorked isotope, just pocketed a $1 billion federal loan courtesy of the Trump administration’s Energy Dominance Financing program. The catch? Restarting the legendary Three Mile Island nuclear reactor—yes, the same site whose cooling towers are as culturally embedded in Pennsylvania as cheesesteak and, once upon a time, existential dread.

    S&P 500’s Nuclear Glow

    Of course, Wall Street noticed. Constellation shares popped faster than a particle in a proton accelerator—mirroring the VanEck Uranium and Nuclear ETF’s uranium-fueled 55% run in 2025, leaving the S&P 500’s 14% gain in the rear-view mirror with all the dignity of a short-seller in a bull market. Tech behemoths like Microsoft (MSFT) have waded in too, eyeing the revived 835-megawatt reactor to power AI data centers—a dazzling marriage of digital ambition and radioactive resolve.

    Three Mile Island Reimagined

    The Three Mile Island site (now rebranded as the Crane Clean Energy Center, because who says nuclear PR can’t have a little panache?) closed in 2019, but never quite faded from the grid or the collective memory. Now, it’s getting the ultimate stimulus package—energy for the grid, jobs for the Mid-Atlantic, and a little piece of regulatory performance art as Constellation guarantees the project’s success, or the taxpayer walks away none the poorer.

    Enter Oklo: The DARPA of Nuclear?

    While Constellation is busy spiffing up yesterday’s infrastructure, Oklo Inc. (OKLO, $102.86, +384.50% YTD) is scripting nuclear’s next act with the flair of a Silicon Valley disruptor who’s seen too many Bond movies. Oklo’s Aurora powerhouse, a sodium-cooled fast reactor designed to run on recycled nuclear fuel, is already laying its foundations at Idaho National Laboratory—complete with a new Siemens Energy turbo-generator contract signed this week, for those who like their power blocks delivered with German precision and American optimism.

    Data Centers and the Aurora Order Book

    Oklo’s ambitions match Constellation’s wattage, but with some subtle startup swagger. The company has inked nonbinding agreements for about 4,750 MW of supply—with data center heavyweights like Equinix and Switch prowling its order book, pushing the pipeline close to 18 gigawatts. Think 21st-century oil rush—except the prospector wears a lab coat and talks about “HALEU” instead of high-octane gasoline.

    The Nuclear Renaissance: High Stakes, High Humor

    Call it a nuclear renaissance, or call it Fission: The Musical. The Energy Department says the Three Mile Island reboot will cut energy costs, create over 600 jobs, and help win the AI arms race—a tall order, but not as ambitious as Oklo’s bid to recycle spent nuclear fuel and peddle it to data centers desperate for a carbon-light edge.

    Constellation gets the glory of reviving a legend, Oklo gets the thrill of building a new one, and somewhere on Wall Street, analysts run the numbers, compare megawatts to mouse clicks, and quietly wonder when uranium stocks will be traded like Taylor Swift concert tickets.

    Nuclear is back, whether you’re nostalgic for the past or betting on the next big thing. Just don’t call it a comeback—the atoms have always been here, waiting for another spin on the grid.

    The Sources…

    1. https://www.investors.com/news/sp-500-nuclear-constellation-energy-trump-administration-three-mile-island-loan/
    2. https://www.foxbusiness.com/politics/trump-admin-provides-1b-federal-loan-restart-three-mile-island-nuclear-reactor
    3. https://www.wsj.com/business/energy-oil/three-mile-island-nuclear-power-plant-ba857bc9
    4. https://www.barrons.com/articles/constellation-energy-stock-three-mile-island-doe-ab37a00b
    5. https://www.cnn.com/2025/11/18/business/three-mile-island-restart-trump
    6. https://www.investing.com/analysis/constellation-energy-strategic-role-in-nuclear-renaissance-drives-upside-200670448
    7. https://www.aol.com/articles/why-constellation-energy-stock-just-165108695.html
    8. https://www.reuters.com/business/energy/us-loans-constellation-1-billion-three-mile-island-reactor-reboot-2025-11-18/
    9. https://www.power-eng.com/nuclear/oklo-taps-siemens-energy-for-steam-cycle-equipment-on-first-aurora-nuclear-project/
    10. https://www.businesswire.com/news/home/20251119322888/en/Oklo-and-Siemens-Energy-Sign-Binding-Contract-to-Expedite-Procurement-of-the-Power-Conversion-System-for-Commercial-Power-Plant
    11. https://finance.yahoo.com/news/oklo-setting-stage-revolution-nuclear-140002716.html
    12. https://oklo.com/newsroom/news-details/2025/Oklo-and-Siemens-Energy-Sign-Binding-Contract-to-Expedite-Procurement-of-the-Power-Conversion-System-for-Commercial-Power-Plant/default.aspx
    13. https://www.investopedia.com/this-energy-provider-is-the-latest-beneficiary-of-trump-nuclear-push-with-usd1b-loan-to-restart-three-mile-island-reactor-ceg-11852498
    14. https://finance.yahoo.com/news/constellation-energy-stock-buy-now-144500390.html
    15. https://www.nytimes.com/2025/11/19/us/nuclear-power-three-mile-island.html
    16. https://www.ans.org/news/tag-constellation%20energy/
    17. https://www.youtube.com/watch?v=7w1x7mPNfoU
    18. https://www.nasdaq.com/articles/oklo-next-millionaire-maker-nuclear-stock
    19. https://oklo.com/newsroom/news-details/2025/Oklo-Announces-U-S–Department-of-Energy-Approval-for-Nuclear-Safety-Design-Agreement-of-Aurora-Fuel-Fabrication-Facility/default.aspx
    20. https://abcnews.go.com/Business/wireStory/energy-department-loans-1b-finance-restart-nuclear-reactor-127650087
    November 19, 2025

    Insulet’s Growth Spurt Meets Modular’s Regulatory Push -( $PODD $MODD $ABT $DXCM )

    Insulet’s (PODD) latest run of press releases reads like a victory lap for a company that has turned tubeless insulin delivery into a global franchise, while Modular Medical (MODD) is quietly trying to crash or expand the same party with a stripped‑down, value‑oriented, easier to use Pivot Patch Pump now stepping into the regulatory spotlight. In diabetes tech terms, Insulet is hosting the conference and Modular is slipping in through the side door with an IRB badge and a 510(k) file folder.

    Insulet: podium position in patch pumps

    Over its last three communications, Insulet has sketched a familiar but enviable picture: Omnipod 5 driving double‑digit top‑line growth, a widening global footprint, and enough investor confidence to justify a dedicated Investor Day at headquarters. Third‑quarter results showed Omnipod sales climbing roughly 30% year over year to just under $700 million, prompting yet another bump to full‑year revenue guidance and reinforcing Insulet’s status as the category’s scale incumbent.

    Strategically, management is signaling that this is not just a pump company, but a consumer‑health platform wrapped around a pod, with expansion into new geographies and additional non‑insulin indications part of the longer‑term roadmap. The upcoming Investor Day is billed as a showcase for that evolution—part factory tour, part strategy seminar, and part reminder that Insulet’s moat is measured in installed base, data, and distribution, not just plastic and electronics.

    Omnipod 5: the high‑end benchmark

    Operationally, Omnipod 5 remains the product to beat, combining automated insulin delivery with tight CGM integration and a fully tubeless, wearable format that Insulet continues to roll out across North America and Europe. In markets like the U.K., Netherlands, and Canada, the system now pairs with both Dexcom (DXCM) and Abbott (ABT) sensors, giving prescribers and patients the rare luxury of choice in a segment where hardware ecosystems typically demand monogamy.

    That combination of algorithmic automation, broad age indications, and smartphone control helps explain why analysts remain comfortable underwriting 20‑plus percent growth off an already large base. It also sets the competitive bar: any challenger patch pump must either offer a meaningfully better experience or a meaningfully lower cost—ideally both—just to get a hearing from payers and clinicians already invested in the Omnipod infrastructure.

    Modular’s Pivot: the budget disruptor

    Enter Modular Medical’s (MODD) Pivot tubeless patch pump, which has now cleared two key milestones in less than a week: FDA 510(k) submission and Institutional Review Board approval for an in‑house insulin delivery study using the commercial‑form device. The company is explicitly aiming at what it calls the “almost‑pumper” segment (~$3B opportunity)—insulin users who have balked at legacy systems on complexity or cost—by promising a simpler, more affordable patch pump with a removable three‑milliliter reservoir and a two‑part, detachable design.

    The near‑term plan is straightforward: gather real‑world usability and performance data under IRB oversight while the FDA digests the 510(k), and prepare manufacturing so that, in a best‑case scenario, commercial launch could follow in early 2026. Importantly, the company is careful to note that Pivot is not yet cleared for sale, underscoring that execution risk still sits squarely with regulators and the company’s ability to scale production and convert those “almost‑pumpers” into paying customers.

    Two patch pumps, one crowded lane

    From a market‑structure perspective, Insulet and Modular are nominally in the same business—tubeless insulin delivery—but increasingly targeting different corners of the runway. Insulet is optimizing a premium, feature‑rich ecosystem that leans into CGM partnerships, software updates, and international expansion; Modular is positioning Pivot as the minimalist alternative for patients who just want reliable basal and bolus delivery without a graduate degree in diabetes tech.

    If Insulet wins by deepening engagement with existing pump users and expanding globally, Modular’s opportunity lies in expanding the total patch‑pump pie by converting injections to pumps in a cost‑conscious cohort that has historically been under‑served. Whether that turns into a complementary dynamic or a competitive collision will depend on how aggressively payers push for lower‑priced options once Pivot is, if ever, on the formulary menu.

    Investor angle: incumbents vs insurgents

    For investors, the setup resembles a familiar medtech narrative: a scaled incumbent delivering clean beats, margin expansion, and a well‑telegraphed capital‑allocation framework, while a micro‑cap insurgent courts attention with regulatory catalysts and promises of a cheaper mousetrap. Insulet’s near‑term story hinges on sustaining mid‑20s revenue growth and translating Omnipod scale into operating leverage, themes likely to be front and center at the November 20 Investor Day.

    Modular Medical (MODD), by contrast, is still in the proving‑ground phase where each press release—an FDA submission here, an IRB approval there—serves as both scientific milestone and investor‑relations oxygen. In a market where tubeless pumps have already gone mainstream, Pivot doesn’t need to dethrone Omnipod so much as demonstrate that there is room, and reimbursement, for a second act in patch‑pump innovation—this time aimed squarely at those who have been almost, but not quite, ready to take the plunge.

    The Sources..

    1. https://finance.yahoo.com/news/modular-medical-receives-irb-approval-133000205.html
    2. https://finance.yahoo.com/news/modular-medical-submits-pivot-tubeless-140000932.html
    3. https://www.businesswire.com/news/home/20251010523598/en/Insulet-to-Host-Investor-Day-on-November-20-2025
    4. https://www.drugdeliverybusiness.com/insulet-q3-2025-increases-guidance-growth/
    5. https://investor.insulet.com/news/news-details/2025/Insulet-Reports-Third-Quarter-2025-Results/default.aspx
    6. https://investors.insulet.com/financials/quarterly-results/default.aspx
    7. https://www.businesswire.com/news/home/20240620287127/en/Insulet-Announces-Full-Commercial-Launch-of-Omnipod-5-with-Expanded-Sensor-Integrations-in-the-United-Kingdom-and-the-Netherlands
    8. https://taurigo.com/stocks/PODD/articles/insulet-investor-day-2025
    9. https://investors.insulet.com/news/news-details/2025/Insulet-Launches-Revolutionary-Omnipod-5-in-Five-More-Countries-in-Europe/default.aspx
    10. https://www.drugdeliverybusiness.com/insulet-fully-launches-omnipod-5-g7-us/
    11. https://www.biospace.com/press-releases/insulet-launches-omnipod-5-automated-insulin-delivery-system-in-canada-a-revolutionary-new-technology-for-people-living-with-type-1-diabetes-ages-two-years-and-above
    12. https://finance.yahoo.com/news/insulet-podd-evaluating-valuation-q3-081219336.html
    13. https://www.nasdaq.com/articles/insulet-stock-post-q3-earnings-revenue-beat-margins-expand
    14. https://www.biospace.com/press-releases/modular-medical-submits-pivot-tubeless-insulin-patch-pump-for-fda-510k-clearance
    15. https://www.stocktitan.net/news/MODD/modular-medical-submits-pivot-tubeless-insulin-patch-pump-for-fda-jm319p26holo.html
    16. https://www.gurufocus.com/news/3209474/modular-medical-modd-advances-with-fda-submission-of-new-pivot-pump
    17. https://finance.yahoo.com/news/insulet-stock-post-q3-earnings-134600813.html
    18. https://investor.insulet.com/overview/default.aspx
    19. https://www.gurufocus.com/news/3212244/modular-medical-modd-gains-irb-approval-for-insulin-delivery-system-study
    20. https://www.biospace.com/press-releases/modular-medical-receives-irb-approval-to-deliver-insulin-using-pivot-patch-pump
    21. https://www.drugdeliverybusiness.com/modular-medical-submits-pivot-pump-fda/
    22. https://biotuesdays.com/2025/11/17/modular-receives-irb-approval-to-deliver-insulin-via-pivot-patch-pump/
    23. https://www.stocktitan.net/news/MODD/modular-medical-receives-irb-approval-to-deliver-insulin-using-pivot-2ck6730o6uzy.html
    24. https://www.omnipod.com/en-gb/1-2-4-release-comms
    25. https://diatribe.org/diabetes-technology/omnipod-5-cleared-fda
    26. https://www.biospace.com/press-releases/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study
    27. https://www.morningstar.com/news/accesswire/1102920msn/modular-medical-receives-irb-approval-to-deliver-insulin-using-pivot-patch-pump
    28. https://www.omnipod.com/en-au/current-podders/resources/omnipod-5/faqs/software-updates
    29. https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/36159839/modular-medical-receives-irb-approval-to-deliver-insulin-using-pivot-patch-pump/
    30. https://www.omnipod.com/current-podders/resources/omnipod-5/faqs/v311-android
    31. https://ir.modular-medical.com/press-release-details.php?newsId=68307ea5-f702-446c-ab63-f4fe9c40c8ae
    32. https://www.omnipod.com/en-gb/current-podders/resources/omnipod-5/faqs/software-updates
    33. https://pedsendo.org/new-meds-and-tech/new-drugs-and-therapeutics-update-omnipod-5-app-now-compatible-with-dexcom-g7/
    34. https://investors.insulet.com/news/default.aspx
    35. https://investor.insulet.com/events-and-presentations/presentations/presentation-details/2025/Insulet-Corporate-Presentation–November-2025/default.aspx
    36. https://investors.insulet.com/news/news-details/2025/Insulet-Champions-Workplace-Inclusion-for-People-with-Diabetes-with-New-Data-and-Tools-Released-for-Diabetes-Awareness-Month/default.aspx
    37. https://www.nasdaq.com/market-activity/stocks/podd/press-releases
    38. https://www.hmenews.com/article/insulet-sees-31-revenue-jump
    39. https://investors.insulet.com/news/news-details/2025/Insulet-Expands-Omnipod-5-to-Four-More-International-Markets/default.aspx
    40. https://finance.yahoo.com/news/insulet-champions-workplace-inclusion-people-080000900.html
    November 19, 2025

    Nvidia’s Blockbuster AI Beat Lifts Wall Street: Stock Market Recap – November 19, 2025 -( $AAPL $EXAS $GOOG $NVDA $OKLO $SER $TSLA $TSM $VIX Rise!)

    U.S. stocks closed Wednesday looking more contemplative than chaotic, as Wall Street tiptoed into the bell ahead of Nvidia’s after-hours earnings—and then promptly exhaled when the AI titan delivered another blockbuster beat. The S&P 500 and Nasdaq finished modestly higher after shaking off early jitters, the Dow lagged as old‑economy names took the brunt of profit‑taking, and small caps quietly outperformed through the Russell 2000, suggesting that not every trader is hiding exclusively in megacap AI royalty.barrons+3​

    Indices and macro backdrop

    By the close, the S&P 500 settled around 6,642.16, up slightly by .38% on the day and clinging to its reputation as the market’s emotional barometer, while the Nasdaq Composite edged .59% higher to 22,564.23 as traders leaned back into chips and software ahead of Nvidia’s print. The Dow finished in the just in the green up .10% at 46,138.77, whereas the Russell 2000 failed to eke out a gain moving .04% lower to 2,347.89 as bargain hunters sifted among beaten‑up small caps for anything resembling mispriced growth.

    The economic calendar remained distorted by the after‑effects of this year’s federal shutdown, with some key releases still shuffled further out on the schedule and investors relying more heavily on high‑frequency indicators and corporate guidance than on a clean run of government data. FOMC‑wise, there was no rate decision on today’s docket, but the market’s attention stayed locked on the coming minutes and the next meeting window, with futures pricing hold at the next meeting and a slower, gentler path to cuts than traders had hoped for a month ago.

    Rates, curve, tariffs and DC

    Treasury yields drifted higher again, pushing the 10‑year toward the upper end of its recent range at 4.142% and the 2‑year at 3.604%.. The move reinforced the “higher for longer” narrative: enough to unsettle richly valued growth shares intraday, but not so violent as to trigger outright capitulation across equities.

    Tariff talk and trade maneuvering stayed in the background, with the administration still exploring targeted tweaks that would ease costs on some consumer imports while keeping broader leverage in place, a compromise that markets greeted with something between a shrug and a polite nod. The shutdown saga, for now, is filed under “temporarily resolved but not forgotten,” as rate‑sensitive sectors continue to trade as if budget brinkmanship could return on short notice.

    Nvidia and the tech complex

    The evening’s main act belonged unmistakably to Nvidia (NVDA, $186.52, +2.85%), which reported another crushing quarter after the close, with revenue and earnings both topping already‑lofty expectations and data‑center demand once again doing the heavy lifting. Management highlighted ferocious appetite for its Blackwell‑generation AI chips—described as “off the charts”—and guided in a way that reassured investors that fears of an imminent AI hardware bust remain premature. Nvidia reported record revenue for the third quarter ended October 26, 2025, of $57.0 billion, up 22% from the previous quarter and up 62% from a year ago. For the quarter, GAAP and non-GAAP gross margins were 73.4% and 73.6%, respectively. For the quarter, GAAP and non-GAAP earnings per diluted share were both $1.30.

    Nvidia shares, which had already firmed into the close, jumped sharply in after‑hours trading to the $193.87 range as options desks scrambled to re‑hedge, and the broader chip complex caught a sympathetic bid in extended hours as well. That late surge set the stage for tomorrow’s open, with traders now debating whether a near‑perfect quarter in the market’s AI bellwether is enough to reset the tone for the entire tech sector—or whether it merely raises the bar for everyone else. During the first nine months of fiscal 2026, NVIDIA returned $37.0 billion to shareholders in the form of shares repurchased and cash dividends. As of the end of the third quarter, the company had $62.2 billion remaining under its share repurchase authorization. NVIDIA will pay its next quarterly cash dividend of $0.01 per share on December 26, 2025, to all shareholders of record on December 4, 2025.

    Individual movers

    Eli Lilly (LLY, $1049.60, +1.90%) spent the session largely in the role of high‑quality bystander, trading sideways to modestly higher as investors continued to view its weight‑loss and diabetes franchises as long‑duration cash‑flow machines rather than sources of short‑term drama. Taiwan Semiconductor’s (TSM, $282.37, +1.60%) U.S. listing tracked the chip tape, firming into the close as investors leaned into the broader AI‑foundry narrative that keeps it at the center of nearly every advanced‑node capacity conversation.

    Alphabet (GOOG) was again strong closing at $292.99, +2.82%. Apple (AAPL, $268.56, +.42%) saw a similar, if milder, pattern as investors weighed its new four‑trillion‑dollar‑club status against the uncomfortable arithmetic of slower device growth and a higher discount rate.

    Tesla (TSLA) traded .68% higher to $403.99 amid a broader cooling in high‑beta growth and ongoing questions about EV demand, margins and corporate drama, while Meta (META, $590.32, -1.23%) drifted in sympathy with other ad‑ and engagement‑driven names. Broadcom, Oracle and Intel were mixed on the day—each still fundamentally lashed to the AI and data‑center story, but now trading stock‑by‑stock as investors differentiate between pure‑play accelerators, networking, and legacy CPU and enterprise software exposure.

    Palantir (PLTR) once again acted like a levered sidecar on AI sentiment, finishing lower by 1.14% to $165.42 after a volatile session as money rotated toward names perceived as software beneficiaries of the same infrastructure wave Nvidia is powering in hardware. At the more speculative end of the tape, Opendoor (OPEN, $6.69,-11.04%) shares fell by double digits and nuclear‑upstart Oklo (OKLO) traded 6.45% higher to $102.86 as Oklo and Siemens Energy announced that they have signed a binding contract for the design and delivery of the power conversion system for Oklo’s Aurora powerhouse. The agreement authorizes Siemens Energy to begin engineering and design work to expedite procurement of long-lead components and initiate the manufacturing process for the power conversion system. This partnership on key components combines Oklo’s expertise in advanced fission technology with Siemens Energy’s industry-leading steam turbine and generator systems to deliver clean, reliable electricity using proven industrial equipment.

    Deals, IPOs, commodities and crypto

    The primary market stayed relatively subdued, with no headline‑grabbing mega‑mergers or splashy NYSE/Nasdaq IPOs to rival the AI earnings spectacle, as prospective issuers continued to wait for a cleaner read on volatility and the Fed’s trajectory. Deal chatter persisted in the background across media, telecom and energy, but nothing crossed the tape that changed the broader equity narrative for the day.

    In commodities, crude oil fell to $59.42, -2.06% as traders reassessed supply risks and demand resilience. Gold at $4,078.40 and silver at $51.04 remained choppy, caught between higher real yields and lingering geopolitical and macro anxiety, leaving each to serve simultaneously as inflation hedge, recession hedge and sometimes‑disappointing portfolio decoration.

    Bitcoin hovered near the psychologically important 90,000 area after recently breaking below prior support, its slide emblematic of how tightly crypto has become correlated with high‑beta tech in a world where rate‑cut hopes keep getting pushed out. For now, the message from today’s tape is clear: the market will tolerate higher yields and macro uncertainty—so long as the AI profit engine, led by Nvidia, continues to deliver numbers that justify the fever dream.

    VP Watchlist Updates

    Modular Medical, Inc. (Nasdaq: MODD., $.4909), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

    Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.20), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

    GeoVax Labs, Inc. (Nasdaq: GOVX, $.4148, +1.67%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

    Volato Group, Inc. (NYSE American: SOAR, $1.12) and M2i Global, Inc. (MTWO, $.0998) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

    Serina Therapeutics (NYSE American: SER, $3.8640, +2.77%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

    The InterGroup Corporation (NASDAQ: INTG, $33.31) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

    Exact Sciences Corp. (NASDAQ: EXAS, $86.18, +23.68%), a leading provider of cancer screening and diagnostic tests, announced (Nov. 7) pivotal clinical validation results from the ALTUS study (NCT: 05064553). The prospective, head-to-head trial demonstrated that the company’s Oncoguard® Liver blood test delivers superior early-stage and overall sensitivity for hepatocellular carcinoma (HCC) — the most common form of liver cancer — compared to the current standard of care.

    Nokia (NOK) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. The market, in classic fashion, responded to this vision of future riches by sending the stock currently lower on the day, but is currently up +45.54% over the last year at $6.04

    The Sources

    https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/35843242/5-top-artificial-intelligence-ai-stocks-to-buy-in-november/

    https://www.barrons.com/livecoverage/stock-market-news-today-111925

    https://www.barrons.com/livecoverage/stock-market-news-today-111925/card/s-p-500-kicks-higher-at-finish-now-its-nvidia-time–pm0tSVrhW1v1Do5z8HMy?mod=bar_FV

    https://www.marketwatch.com/livecoverage/stock-market-today-dow-sp500-nasdaq-steady-after-4-day-losing-streak-nvidia-earnings/card/s-p-500-futures-show-sell-off-stalled-as-traders-eye-nvidia-results-2WGvK0bxH6LrBygDrEZw

    https://finance.yahoo.com/quote/%5EGSPC/history/

    https://www.thestreet.com/latest-news/stock-market-today-nasdaq-sp-500-futures-turn-to-upside-as-nvidia-earnings-loom

    https://us.plus500.com/newsandmarketinsights/global-stocks-fall-tech-bitcoin-oil-november-2025

    https://www.bls.gov/bls/2025-lapse-revised-release-dates.htm

    https://tradingeconomics.com/united-states/calendar

    https://www.census.gov/economic-indicators/calendar-listview.html

    https://www.marketwatch.com/economy-politics/calendar

    https://www.newyorkfed.org/research/calendars/nationalecon_cal

    https://www.bea.gov

    https://www.wsj.com/livecoverage/nvidia-earnings-stock-market-today-11-19-2025

    https://www.globenewswire.com/news-release/2025/11/19/3191444/0/en/NVIDIA-Announces-Financial-Results-for-Third-Quarter-Fiscal-2026.html

    https://finance.yahoo.com/news/nvidia-announces-financial-results-third-212000333.html

    https://www.tipranks.com/news/nvda-earnings-nvidia-q3-revenues-surpass-50b-beats-earnings-estimates

    https://uk.finance.yahoo.com/news/earnings-live-nvidia-q3-results-beat-ceo-jensen-huang-says-blackwell-chip-demand-is-off-the-charts-213245875.html

    https://www.businessinsider.com/nvidia-q3-earnings-live-updates-nvda-stock-price-ai-chips-2025-11

    https://www.investopedia.com/nvidia-earnings-live-coverage-q3-fy2026-11852941

    https://www.cnbc.com/2025/11/19/nvidia-reports-third-quarter-results-after-the-bell-heres-what-wall-street-expects-.html

    https://finance.yahoo.com/news/stock-market-news-nov-19-143100915.html

    https://www.youtube.com/watch?v=TH707KA8CGs

    https://swingtradebot.com/news-articles/22267452-dow-jones-hits-record-close-palantir

    https://x.com/stats_feed/status/1983188044019630372

    https://www.governance-intelligence.com/shareholders-activism/week-grc-tesla-sets-november-date-2025-agm-amid-corporate-turmoil

    https://polymarket.com/event/pltr-up-or-down-on-november-19-2025/pltr-up-or-down-on-november-19-2025

    https://stockanalysis.com/stocks/pltr/history/

    https://www.eoption.com/morning-preview-november-19-2025/

    https://www.economies.com/crypto/analysis/evening-update-for-bitcoin-(btcusd)–19-11-2025-122806

    https://www.investing.com/analysis/bitcoin-weakness-echoes-through-gold-as-traders-react-to-fed-signals-200670418

    https://economictimes.com/news/international/us/bitcoin-ether-and-solana-all-crashing-hard-as-more-than-1-trillion-lost-why-crypto-prices-are-falling-so-sharply-and-how-long-could-this-crypto-correction-last/articleshow/125444030.cms

    https://www.reuters.com/business/us-stock-futures-slip-rate-cut-hopes-fade-valuation-worries-persist-2025-11-18/

    https://www.morningstar.com/news/marketwatch/20251118110/the-sp-500-and-dow-extend-their-losing-streaks-to-a-fourth-day-are-stocks-headed-for-a-full-10-correction

    https://www.cnbc.com/2025/11/17/stock-market-today-live-updates.html

    https://www.bloomberg.com/news/articles/2025-11-18/stock-market-today-dow-s-p-live-updates

    https://finance.yahoo.com/news/november-technology-portfolio-launches-insights-110000020.html

    https://www.home.saxo/content/articles/macro/market-quick-take—19-november-2025-19112025

    November 19, 2025

    Nokia Targets 60% Profit Lift by 2028 as It Rolls Out AI‑Ready Networks -( $NOK $NVDA $SPY )

    Nokia (NOK) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. The market, in classic fashion, responded to this vision of future riches by sending the stock currently lower on the day, but is currently up +45.54% over the last year at $6.04.

    Big profit promises, modest patience

    By 2028, Nokia wants to grow its comparable operating profit to a range of roughly €2.7 billion to €3.2 billion, up from about €2.0 billion over the last 12 months—a target that sounds ambitious until one remembers how many network cycles the company has already lived through. The goal implies a potential profit boost of up to about 60%, built on higher-margin network gear and tighter cost control rather than a sudden global love affair with telecom capex.

    Two segments, one makeover

    To get there, Nokia is stripping its structure down to two primary operating segments—Network Infrastructure and Mobile Infrastructure—starting in 2026, a move executives say will sharpen focus and speed decisions as AI and data centers soak up ever more bandwidth. Several smaller units, from fixed wireless CPE to microwave radio, are being shunted into “portfolio businesses” pending strategic decisions, corporate code for “for sale, to be partnered, or put on a strict performance diet.”

    Chasing the AI supercycle

    The official strategy now revolves around the “AI supercycle,” with Nokia pledging to accelerate growth in AI and cloud, lead the next era of mobile connectivity with AI‑native networks and 6G, and co‑innovate with customers who increasingly look more like hyperscalers than legacy phone companies. Network Infrastructure is expected to grow net sales at a 6–8% annual clip from 2025 to 2028, with optical and IP networks targeted for a double‑digit growth rate as data centers demand fatter, faster pipes.

    Margins, KPIs and a skeptical Street

    On the numbers, Nokia is aiming for a 13–17% operating margin in Network Infrastructure and a 48–50% gross margin in Mobile Infrastructure by 2028, while cutting group “common and other” operating expenses to €150 million from about €350 million. Analysts, however, have already flagged the 2028 targets as underwhelming, a reminder that investors have grown used to confident long‑term plans from gear makers and slightly less confident delivery, particularly when mobile networks are still digesting prior 5G splurges.

    From networks to narrative

    For now, Nokia’s story is that of a once‑ubiquitous consumer brand recasting itself—again—as the quiet plumbing behind AI‑driven connectivity, hoping investors will pay more for pipes if they are branded “AI‑ready.” Whether the new structure and targets mark the beginning of an AI‑era rerating or just another chapter in Nokia’s long history of reinvention will depend less on slideware and more on whether, by 2028, those promised margins look like engineering reality rather than marketing copy.

    By the way, note that Nvidia (NVDA) has made a $1 billion equity investment that secured a 2.9% stake in Nokia….

    The Sources…

    1. https://www.reuters.com/business/nokia-sets-new-long-term-annual-profit-target-2025-11-19/
    2. https://uk.finance.yahoo.com/news/nokia-stock-falls-today-cmd-141414501.html
    3. https://www.nokia.com/newsroom/nokia-announces-new-strategy-evolution-of-its-operating-model-new-long-term-financial-target-strategic-kpis-and-changes-to-its-group-leadership-team/
    4. https://www.benzinga.com/markets/commodities/25/11/48953838/nokia-stock-drops-after-restructuring-plan-and-fresh-profit-targets
    5. https://www.portugalpulse.com/nokia-will-restructure-operations-and-advances-with-a-new-strategy-based-on-ai/
    6. https://www.ainvest.com/news/nokia-strategic-reorientation-ai-driven-connectivity-pathway-long-term-creation-2511/
    7. https://www.marketscreener.com/news/nokia-shares-plunge-following-disappointment-over-new-financial-targets-ce7d5ed9d980ff23
    8. https://www.nokia.com/system/files/2025-10/nokia_results_2025_q3.pdf
    9. https://www.nokia.com/newsroom/nokia-corporation-report-for-q2-and-half-year-2025/
    10. https://www.nasdaq.com/articles/nokia-issues-new-long-term-financial-target-operate-two-primary-operating-segments
    11. https://www.investing.com/news/company-news/nokia-outlines-new-strategy-with-twosegment-structure-93CH-4367168
    12. https://www.nokia.com/newsroom/inside-information-nokia-provides-an-update-on-group-strategy-2026-comparable-operating-margin-target-and-preliminary-assumptions-for-2024/
    13. https://seekingalpha.com/news/4400702-nokia-outlines-1b-data-center-sales-goal-by-2028-amid-heightened-investments
    14. https://www.nokia.com/system/files/2025-07/nokia_results_2025_q2.pdf
    15. https://www.nokia.com/about-us/investors/investor-relations-events/
    16. https://www.fitchratings.com/research/corporate-finance/fitch-affirms-nokia-at-bbb-outlook-stable-08-09-2025
    17. https://www.nokia.com/newsroom/nokia-corporation-interim-report-for-q1-2025/
    18. https://www.nokia.com/about-us/investors/
    19. https://events.nokia.com/855364
    20. https://www.wsj.com/business/nokia-takes-aim-at-data-center-market-with-pledge-to-increase-investments-0b6aac6a
    November 18, 2025

    Recycling as a Resource: Inside EverMetal’s Bid to Turn Trash Into Treasure -( $MTWO $SOAR )

    For decades, recycling was the domain of earnest suburban homeowners and aluminum can loyalists. But now, amid geopolitical scrambles for lithium, nickel, and cobalt, the practice has graduated from hobby to high finance. In the latest episode of The Minerals Metals Initiative, Hugo Schumann—CEO and founder of EverMetal Capital—lays out a vision where old circuit boards and discarded batteries become the building blocks of America’s next industrial boom.

    A Clean Loop

    Schumann, who also leads Elemental Group USA and manages nearly 50 recycling sites nationwide, describes his company’s goal with the crisp confidence of a fund manager discussing an overlooked asset class. EverMetal styles itself as the world’s first private equity–backed critical metals recycling platform—a title that sounds equal parts MBA dream and sustainability manifesto. The mission: turn the messy business of scrap into a clean loop for the digital age. The same rare metals pulled from remote mines could one day return through collection networks, ready for a second life in electric vehicles, smartphones, and wind turbines.

    Practical & Urgent

    It’s a vision that feels both practical and urgent. As the U.S. rushes to secure supply chains for critical materials—many of which are sourced from geopolitically delicate corners of the world—the ability to reclaim metals domestically has become less an environmental ideal and more an economic necessity. But to do that, Schumann insists, the nation needs two balancing forces: better collection systems and smarter consumer incentives. Without them, far too many obsolete gadgets will remain in closets instead of rejoining the mineral supply chain.

    The Sum..

    The episode, titled “Recycling as a Resource: Critical Metals Recycling and the Circular Economy,” runs like a master class in modern material strategy. It’s also refreshingly pragmatic, stripping sustainability of its buzzwords and treating it instead as shrewd resource management—a discipline Wall Street might finally take seriously.

    USA flag with 'Critical-Minerals' enclosed in a circle overlay.

    Further Afield: Volato and M2i Global Advance Development of Strategic Mineral Reserve Digital Infrastructure

    Volato Group, Inc. (NYSE American: SOAR) (“Volato”) and M2i Global, Inc. (OTCQB: MTWO) (“M2i”) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations.

    This infrastructure is being developed to serve as the market-facing layer of the U.S. Critical Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

    Unlike securities or commodities exchanges, this system focuses exclusively on physical materials. It enables direct contracting, leasing, collateralization, and trust-held arrangements between qualified participants, without trading or listing securities, futures, or derivatives—ensuring clear compliance with U.S. and allied regulatory frameworks.

    Building on Volato’s expertise in scalable aviation software and real-time asset tracking, Volato and M2i are beginning development of the core transaction and data-integrity systems. M2i continues to lead policy alignment and participant onboarding, while Volato engineers the secure digital infrastructure. By combining Volato’s proven enterprise systems with M2i’s CAINO (Critical Asset Intelligence and Network Operations) compliance stack, the unified team will deliver a secure framework for data exchange, verification, and auditable material movement—creating transparent chains of custody from mine to manufacturer.

    “This project represents the convergence of M2i’s critical-minerals strategy and Volato’s track record in building auditable, high-value operational systems,” said Matt Liotta, Co-Founder and CEO of Volato. “Our team is now turning M2i’s blueprint into a working platform that brings transparency and accountability to one of the world’s most strategic supply chains.”

    “With Volato leading software development, this effort moves from concept to construction,” said Major General (Ret.) Alberto Rosende, CEO of M2i Global. “This collaboration combines industrial vision with execution capability.”

    By combining Volato’s digital infrastructure with M2i’s strategic and operational framework, this initiative addresses one of today’s most pressing industrial challenges: establishing a reliable, transparent supply of materials essential to defense, energy, and technology manufacturing.

    This development effort follows the previously announced definitive business combination between Volato and M2i Global, under which Volato will acquire 100% of M2i’s outstanding equity in an all-stock transaction. Upon closing, M2i shareholders are expected to own approximately 85% of the combined company and Volato shareholders approximately 15%. The Boards of both companies have approved the transaction, which remains subject to regulatory review and shareholder approval.

    Your Guide To Staying Informed In The Markets

    Subscribe For Free Email Updates Access To Exclusive Research

    Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

    Copyright © 2026 Vista Partners, LLC. All rights reserved